

KIDNEY CANCER RESEARCH PROGRAM (KCRP)

**ADVANCING INNOVATIVE RESEARCH
TO ELIMINATE KIDNEY CANCER**

MISSION: To promote rigorous, innovative, high impact research in kidney cancer for the benefit of Service Members, Veterans, and the American public



CDMRP
DEPARTMENT OF DEFENSE
CONGRESSIONALLY DIRECTED
MEDICAL RESEARCH PROGRAMS

**FY23
Appropriation
\$50M**

FY23 KCRP Funding Mechanisms



**Clinical Consortium
Award (CCA)**


Coordinating Center

\$6.0M*

Clinical Site

\$800K*

CCA TIMELINE



* The institutions will receive an initial payment from FY23 appropriations; exercise of options will be based on meeting performance metrics as specified in the award agreements.

Highlights of the CCA

- Supports a consortium to facilitate the rapid execution of collaborative phase 1 and 2 clinical trials that will bring to market high-impact, novel therapeutics that will ultimately and significantly decrease the impact of kidney cancer.
- One coordinating center and up to six clinical research sites will be selected. All sites are jointly responsible for proposing, selecting, and conducting trials.
- Coordinating center and clinical research sites must provide plans for accruing patients from populations disproportionately affected by kidney cancer and/or military populations.
- Trials that incorporate investigations of biomarkers for risk assessment, early detection, prediction, or aggressiveness, and/or progression of kidney cancer are encouraged.
- Submissions from institutions with enhanced access to patients from high-risk, underserved, and/or military populations (as described in the FY23 KCRP Strategic Goals and Focus Areas) are especially encouraged.

FY23 KCRP Focus Areas

Fiscal year 2023 (FY23) applicants are required to address at least one of the FY22 KCRP Focus Areas:



Conduct basic biology research in kidney cancer to better understand the disease.



Identify and develop new strategies for screening, early detection, accurate diagnosis and prognosis prediction of kidney cancers.



Define biology of rare kidney cancers and develop treatments to improve outcomes and reduce death.



Develop novel therapeutic strategies for kidney cancer, such as novel drug treatment combinations, and delivery systems.



Identify and implement strategies to improve quality of life and survivorship.



Identify and implement strategies to mitigate health disparities in treatment access; and understanding social, cultural, environmental and biological contributors.



Increase research capacity through support of next generation and cultivating kidney cancer research.

For more information about the KCRP, please visit
cdmrp.health.mil/kcrp

